1 / 8

Pendred Syndrome (PS) Market

Pendred Syndrome (PS) Market by Treatment (Cochlear Implant, Hearing Aids, and Radioactive Iodine) Route of Administration (Oral, Implantation), Diagnosis (Genetic Testing, Perchlorate Washout Test, and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Otolaryngologist, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Vibhavjodh16
Download Presentation

Pendred Syndrome (PS) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pendred Syndrome (PS) Market – Trends and Forecast Till 2030 sales@delvens.comwww.delvens.com

  2. Pendred Syndrome (PS) Market – Trends and Forecast Till 2030 Pendred Syndrome (PS) Market by Treatment (Cochlear Implant, Hearing Aids, and Radioactive Iodine) Route of Administration (Oral, Implantation), Diagnosis (Genetic Testing, Perchlorate Washout Test, and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Otolaryngologist, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). Request For Free Sample Report:https://www.delvens.com/get-free-sample/pendred-syndrome-ps-market sales@delvens.com www.delvens.com

  3. Market Overview The global Pendred Syndrome (PS) market size was estimated at USD 2.82 billion in 2023 and is projected to reach USD 3.83 billion in 2030 at a CAGR of 4.5% during the forecast period 2023-2030. Pendred syndrome, often abbreviated to PS, is a rare genetic disorder characterized by a combination of sensorineural hearing loss and thyroid dysfunction. It is named after British physician Vaughan Pendred, who first described the syndrome in the early 20th century. Pendred syndrome is caused by mutations in the SLC26A4 gene, also known as the pendrin gene. This gene codes for a protein called pendrin, which plays a critical role in the transport of ions (charged particles) through the cell membranes of the cochlea and thyroid gland. Purchase this Report:https://www.delvens.com/checkout/pendred-syndrome-ps-market sales@delvens.com www.delvens.com

  4. Key Findings The Treatment segment is further fragmented into Cochlear Implant, Hearing Aids, and Radioactive Iodine. The Cochlear Implant segment is expected to account for a larger market size during the forecast period. Cochlear implants are electronic devices that are surgically implanted into the inner ear to provide a sense of sound for individuals with severe to profound hearing loss. The diagnosis segment is further bifurcated into Genetic Testing, Perchlorate Washout Test, and Others. The Genetic Testing is the largest market during the forecast period. Genetic testing is a crucial tool in diagnosing Pendred Syndrome. This involves analyzing the DNA of an individual to identify mutations in the SLC26A4 gene, which is associated with the syndrome. The End- Users segment is further bifurcated into Hospitals, Homecare, Specialty Clinics, Otolaryngologist, and Others. The Hospitals is the largest market during the forecast period. Hospital-based otolaryngologists (ear, nose, and throat specialists) can assess the severity of hearing loss, conduct inner ear imaging, and provide guidance on treatment options, including hearing aids and cochlear implants. sales@delvens.com www.delvens.com

  5. Key Findings The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period owing to the rising healthcare costs, increased R & D, and trending technological advancements. Inquire Before Buying:https://www.delvens.com/Inquire-before-buying/pendred-syndrome-ps-market sales@delvens.com www.delvens.com

  6. Competitive Landscape • Nobel pharma Co.,Ltd • Sensorion • Advanced Bionics AG • MED-EL Medical Electronics • Cochlear Ltd • Sonova • GAES • Demant A/S • Nurotron Biotechnology Co. Ltd • GN Store Nord A/S sales@delvens.com www.delvens.com

  7. Recent Developments Biotechnology Companies: Biotechnology companies may focus on advancing gene therapy approaches for Pendred Syndrome. This includes research into gene editing technologies, viral vectors, and delivery mechanisms to correct or replace the faulty SLC26A4 gene in affected individuals. Research Institutions and Academia: Academic institutions and research organizations play a significant role in studying rare genetic disorders like Pendred Syndrome. Their contributions may include conducting studies to understand the underlying mechanisms of the disease, exploring potential therapeutic targets, and collaborating with industry partners to translate research findings into clinical applications. sales@delvens.com www.delvens.com

  8. Contact Information About Us: Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally. Contact Us: +44-20-3290-6466 +1 214-377-1144 sales@delvens.com sales@delvens.com www.delvens.com

More Related